​

CERo Therapeutics Stock (NASDAQ:CERO)

FinancialsChart
CERo Therapeutics by TradingView

Previous Close

$0.07

52W Range

$0.06 - $896.00

50D Avg

$4.68

200D Avg

$14.74

Market Cap

$145.85K

Avg Vol (3M)

$2.17M

Beta

0.32

Div Yield

-

CERO Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Nov 30, 2021

Website

CERO Performance

CERO Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-16.20M$-2.93M$-2.91M
Net Income$-11.09M$-2.54K$-667.74K
EBITDA$-16.20M$-2.44M$-68.58K
Basic EPS-$-0.39$-0.10
Diluted EPS-$-0.39$-0.10

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
LIMNLiminatus Pharma, Inc. Class A Common Stock
OCEAOcean Biomedical, Inc.
XRTXXORTX Therapeutics Inc.
GLMDGalmed Pharmaceuticals Ltd.
BIVIBioVie Inc.
MLECMoolec Science S.A.
PTIXProtagenic Therapeutics, Inc.
ELABPMGC Holdings Inc.